Evidence map›Paper›PMID 37701241›Full record

ArticleFood science & nutrition2023

Glycemic index of a nutritional supplement designed for people with chronic kidney disease.

Bhoite Rachana, Shanmugam Shobana, Pratti Varalakshmi Lalithya, Vasudevan Sudha, Satyavrat Vinita, Rajagopal Gayathri, Natarajan Kalpana, Mohan Anjana Ranjit, Mohan Viswanathan

Open access · hybridAbstract read
In one paragraph

Article in Food science & nutrition, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Bhoite RachanaDr. Reddy's Laboratories Pvt Ltd. Hyderabad Telangana India.ORCID https://orcid.org/0000-0001-5291-6799
Shanmugam ShobanaDepartment of Foods Nutrition & Dietetics Research, Madras Diabetes Research Foundation Chennai Tamil Nadu India.
Pratti Varalakshmi LalithyaDr. Reddy's Laboratories Pvt Ltd. Hyderabad Telangana India.
Vasudevan SudhaDepartment of Foods Nutrition & Dietetics Research, Madras Diabetes Research Foundation Chennai Tamil Nadu India.
Satyavrat VinitaDr. Reddy's Laboratories Pvt Ltd. Hyderabad Telangana India.
Rajagopal GayathriDepartment of Foods Nutrition & Dietetics Research, Madras Diabetes Research Foundation Chennai Tamil Nadu India.
Natarajan KalpanaDepartment of Foods Nutrition & Dietetics Research, Madras Diabetes Research Foundation Chennai Tamil Nadu India.
Mohan Anjana RanjitDepartment of Foods Nutrition & Dietetics Research, Madras Diabetes Research Foundation Chennai Tamil Nadu India.
Mohan ViswanathanDepartment of Foods Nutrition & Dietetics Research, Madras Diabetes Research Foundation Chennai Tamil Nadu India.
Madras Diabetes Research Foundation · INDr. Reddy's Laboratories (India) · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The study was carried out to measure the glycemic index (GI) of an oral food supplement for people with CKD as well as on patients on maintenance dialysis. The study was conducted as per international protocols for testing GI, was approved by the local institutional ethics committee, and was registered with the Clinical Trial Registry of India (CTRI). This was a crossover randomized controlled study which enrolled 15 participants between the ages of 18 and 45 years. The participants were randomly allotted to one group that consumed either the reference food (27.5 g of glucose monohydrate) or 118 g of the nutritional supplement which contained 25 g of available carbohydrates. Fasting capillary blood samples as well as blood samples at different time intervals as per the GI protocol, after consumption of either the supplement or the reference food were taken from the participants. Each testing day was separated by a 3-day washout period. GI was calculated from the incremental area under the blood glucose response elicited by the nutritional supplement as a percentage of the response after the consumption of 25 g of glucose (27.5 g of glucose monohydrate) by the same participant using a standard formula. The GI of the nutritional supplement was calculated to be 10.3 ± 2.0 which is considered to be low as per international GI testing standards. The product was created to supplement the diet of people with CKD at different stages and to help prevent the progression from CKD to ESRD as well as the risk for CVD. This product was found to have a low GI which is desirable for people with CKD as well as diabetics in general who are at risk for developing CKD.

Indexed as

chronic kidney diseaseglycemic indexnephropathynutritional supplementrenal nutrition

Identifiers

PMID37701241
PMCPMC10494616
OpenAlexW4385582472

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.